(3aR,4R,5R,6aS)-5-benzyloxy-1-methyloxycarbonyl-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside | 736968-58-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (3aR,4R,5R,6aS)-5-benzyloxy-1-methyloxycarbonyl-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside
• 英文别名: (3aR,4R,5R,6aS)-5-Benzyloxy-1-methyloxycarbonyl-hexahydro-cyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-beta-D-glucopyranosyl)-alpha-D-glucopyranoside；methyl (3aR,4R,5R,6aS)-4-[(2S,3R,4S,5R,6R)-5-[(2S,3R,4S,5R,6R)-6-methyl-3,4,5-tris(phenylmethoxy)oxan-2-yl]oxy-3,4-bis(phenylmethoxy)-6-(phenylmethoxymethyl)oxan-2-yl]oxy-5-phenylmethoxy-3,3a,4,5,6,6a-hexahydrocyclopenta[c][1,2]oxazole-1-carboxylate
• CAS: 736968-58-4
• 化学式: C₆₉H₇₅NO₁₄
• 分子量: 1142.35
• InChiKey: NHMAAUHROVRVIS-DSXGDVBLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.1
• 重原子数：
  84
• 可旋转键数：
  27
• 环数：
  11.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  140
• 氢给体数：
  0
• 氢受体数：
  14

反应信息

• 作为反应物：
  描述：

  (3aR,4R,5R,6aS)-5-benzyloxy-1-methyloxycarbonyl-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside 在 氢氧化钾 、 氯化铵 作用下， 以 甲醇 、 水 为溶剂， 反应 8.0h， 以91%的产率得到(3aR,4R,5R,6aS)-5-benzyloxy-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside
  参考文献：
  名称：

  OLIGOSACCHARIDE DERIVATIVE

  摘要：

  公开号：

  EP1589023B1
• 作为产物：
  描述：

  (3aR,4R,5R,6aS)-5-benzyloxy-1-benzyloxycarbonyl-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-D-glucopyranoside 在 sodium methylate 、 Dowex 50W X 8 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 0.67h， 以47%的产率得到(3aR,4R,5R,6aS)-5-benzyloxy-1-methyloxycarbonyl-hexahydrocyclopenta[c]isoxazol-4-yl 2,3,6-tri-O-benzyl-4-O-(2,3,4-tri-O-benzyl-6-deoxy-β-D-glucopyranosyl)-α-D-glucopyranoside
  参考文献：
  名称：

  OLIGOSACCHARIDE DERIVATIVE

  摘要：

  公开号：

  EP1589023B1

文献信息

• Oligosaccharide derivative
  申请人：Honda Takeshi

  公开号：US20060025350A1

  公开（公告）日：2006-02-02

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有化学式（I）的化合物：其中A代表环状基团，R1和R2代表烷基或羟甲基等基团，n代表1或2，或其药学上可接受的盐或酯具有卓越的活性和稳定性，并且可用于治疗和/或预防糖尿病等疾病。
• Medicinal Composition Containing Diabeted Remedy
  申请人：Izumi Masanori

  公开号：US20080039367A1

  公开（公告）日：2008-02-14

  A pharmaceutical composition effective for the prophylaxis and treatment of diabetes is provided. This pharmaceutical composition comprises the combination of an α-amylase inhibitor selected from a compound represented by the following general formula (I): [wherein A represents, for example, a cyclic group, etc. R 1 and R 2 represent an alkyl group, hydroxymethyl group, etc., and n represents 1 or 2], or a pharmacologically acceptable salt or ester thereof, and at least one type of drug selected from an insulin sensitizer, an insulin secretagogue, a biguanide drug, an insulin preparation and a DPP-IV inhibitor.

  提供一种用于预防和治疗糖尿病的药物组合物。该药物组合物包括以下通用式（I）所表示的化合物中选择的α-淀粉酶抑制剂：[其中A代表环状基团等，R1和R2代表烷基、羟甲基基团等，n代表1或2]，或其药理学上可接受的盐或酯，以及选择自胰岛素增敏剂、胰岛素分泌促进剂、双胍类药物、胰岛素制剂和DPP-IV抑制剂中的至少一种药物。
• Oligosaccharide Derivative
  申请人：Honda Takeshi

  公开号：US20080194495A1

  公开（公告）日：2008-08-14

  Compounds having the formula (I): wherein A represents a group such as a cyclic group, R 1 and R 2 represent groups such as alkyl groups or hydroxymethyl groups, and n represents 1 or 2, or pharmacologically acceptable salts thereof or pharmacologically acceptable esters thereof have superior activity and stability, and are useful for the treatment and/or prevention of diabetes mellitus, or the like.

  具有式(I)的化合物：其中A表示环状基团，R1和R2表示烷基或羟甲基等基团，n表示1或2，或其药学上可接受的盐或酯，在活性和稳定性方面具有优越性，可用于治疗和/或预防糖尿病等疾病。
• US7361744B2
  申请人：——

  公开号：US7361744B2

  公开（公告）日：2008-04-22
• US7632930B2
  申请人：——

  公开号：US7632930B2

  公开（公告）日：2009-12-15